IL319844A - Compounds and compositions useful as IAPS inhibitors - Google Patents
Compounds and compositions useful as IAPS inhibitorsInfo
- Publication number
- IL319844A IL319844A IL319844A IL31984425A IL319844A IL 319844 A IL319844 A IL 319844A IL 319844 A IL319844 A IL 319844A IL 31984425 A IL31984425 A IL 31984425A IL 319844 A IL319844 A IL 319844A
- Authority
- IL
- Israel
- Prior art keywords
- iaps
- inhibitors
- compounds
- compositions useful
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263411550P | 2022-09-29 | 2022-09-29 | |
| PCT/US2023/034219 WO2024073106A1 (en) | 2022-09-29 | 2023-09-29 | Compounds and compositions useful as inhibitors of taps |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319844A true IL319844A (en) | 2025-05-01 |
Family
ID=90479010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319844A IL319844A (en) | 2022-09-29 | 2023-09-29 | Compounds and compositions useful as IAPS inhibitors |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4593818A1 (de) |
| JP (1) | JP2025535017A (de) |
| KR (1) | KR20250093324A (de) |
| CN (1) | CN120302969A (de) |
| AU (1) | AU2023350829A1 (de) |
| IL (1) | IL319844A (de) |
| MX (1) | MX2025003568A (de) |
| WO (1) | WO2024073106A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025090605A1 (en) * | 2023-10-24 | 2025-05-01 | University Of Houston System | Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19 |
| TW202547480A (zh) * | 2024-04-08 | 2025-12-16 | 美國休士頓系統大學 | 可用於治療增殖性疾病或病症之化合物及組合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008134679A1 (en) * | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
| JP6817288B2 (ja) * | 2015-08-10 | 2021-01-20 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 新規な連結体及び生体分子と薬物との特異的共役におけるその使用 |
-
2023
- 2023-09-29 CN CN202380070237.4A patent/CN120302969A/zh active Pending
- 2023-09-29 KR KR1020257013853A patent/KR20250093324A/ko active Pending
- 2023-09-29 IL IL319844A patent/IL319844A/en unknown
- 2023-09-29 JP JP2025518779A patent/JP2025535017A/ja active Pending
- 2023-09-29 EP EP23873679.7A patent/EP4593818A1/de active Pending
- 2023-09-29 AU AU2023350829A patent/AU2023350829A1/en active Pending
- 2023-09-29 WO PCT/US2023/034219 patent/WO2024073106A1/en not_active Ceased
-
2025
- 2025-03-26 MX MX2025003568A patent/MX2025003568A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4593818A1 (de) | 2025-08-06 |
| AU2023350829A1 (en) | 2025-04-03 |
| WO2024073106A8 (en) | 2024-11-07 |
| CN120302969A (zh) | 2025-07-11 |
| MX2025003568A (es) | 2025-07-01 |
| JP2025535017A (ja) | 2025-10-22 |
| KR20250093324A (ko) | 2025-06-24 |
| WO2024073106A1 (en) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL318748A (en) | Compositions and methods for inhibiting KRAS | |
| ZA202210224B (en) | Chelator compositions for radiometals and methods of using same | |
| IL319844A (en) | Compounds and compositions useful as IAPS inhibitors | |
| IL321319A (en) | Compounds and preparations as c-kit kinase inhibitors | |
| IL317736A (en) | Compounds as AXL inhibitors | |
| MX2023011014A (es) | Inhibidores de heteroarílo de la calicreína plasmática. | |
| IL321357A (en) | KIF18A inhibitors and their uses | |
| GB202014160D0 (en) | Senolytic compounds and compositions | |
| IL326424A (en) | Pharmaceutical compounds and preparations as C-KIT kinase inhibitors | |
| IL304159A (en) | A preparation containing bl-8040 | |
| IL316934A (en) | Compounds and methods for inhibiting MAPT expression | |
| EP4172329A4 (de) | Zusammensetzungen zur genomeditierung und verfahren zur verwendung davon | |
| IL300953B1 (en) | Compounds and preparations as SPPL2A inhibitors | |
| HK40128730A (en) | Compounds and compositions useful as inhibitors of iaps | |
| PT4136091T (pt) | Formas e composições de inibidores da calicreína plasmática | |
| EP4294405A4 (de) | Zusammensetzungen und verbindungen zur gemeinsamen verabreichung von uridin und ketoleucin | |
| IL317852A (en) | 3-βHSD1 inhibitors and compositions and uses thereof | |
| HK40095943A (en) | Compounds and compositions as sppl2a inhibitors | |
| CA3273354A1 (en) | COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF | |
| CA3273357A1 (en) | COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF | |
| GB202311665D0 (en) | Modification of composition | |
| HK40100055A (en) | Compositions for and methods of inhibiting sars-cov2 infection | |
| HK40108103A (en) | Compositions comprising mixtures of compounds and uses thereof | |
| CA3299146A1 (en) | Compositions and methods for inhibiting expression of pd-l1 | |
| IL325884A (en) | Compositions comprising GAL475 and methods of using them |